ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

A Proof-of-Principle Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)

A. Chruscinski1, S. Juvet1, S. Moshkelgosha1, E. Renner1, L. Lilly1, N. Selzner1, C. Bredeson2, O. Adeyi1, S. Fischer1, A. Demetris3, J. Zhang1, M. Epstein1, A. Clement2, K. Khalili1, Z. Galvin1, A. Humar1, T. Kim1, K. Tinckham1, T. Yi1, G. Levy1, H. Atkins2

1Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, 2The Ottawa Hospital, Ottawa, ON, Canada, 3University of Pittsburgh, Pittsburgh, PA

Meeting: 2020 American Transplant Congress

Abstract number: 466

Keywords: Liver transplantation, T cell receptors (TcR), Tolerance

Session Information

Date: Saturday, May 30, 2020

Session Name: Tolerance

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

Related Abstracts
  • An Open-Label Proof-of-Principle Phase 2a Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)
  • An Open-Label Proof-of-Principle Phase 2A Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT)

*Purpose: Long-term survival of recipients of solid organ transplants is limited by chronic rejection, disease recurrence and immunosuppression-induced toxicity. Self-tolerance is established after autologous hematopoietic stem cell transplantation (aHSCT) for patients with autoimmune disease. We studied whether aHSCT can induce tolerance in liver transplant recipients.

*Methods: Patients enrolled had previously undergone liver transplantation for primary sclerosing cholangitis (PSC) and now had evidence of PSC recurrence. These patients were chosen given the poor outcomes associated with PSC recurrence. Eligible patients were greater than three months post-liver transplant and were between 18 to 55 years old. Hematopoietic stem cells were mobilized, isolated using CD34 cell immunomagnetic selection, and cryopreserved. Busulfan, cyclophosphamide and rabbit anti-thymocyte globulin were administered followed by aHSCT. Immunosuppressive medications were discontinued at the time of HSCT and everolimus was given to promote regulatory T cell (Treg) expansion for the first six months.

*Results: Twelve patients were evaluated and five were accepted for aHSCT. All five patients had evidence of recurrent PSC with moderate to severe ductopenia and fibrosis. Patients received a mean 7.21×106 purified CD34/kg. Of the five patients enrolled, three developed tolerance: two patients are off immunosuppression for greater than three years post-aHSCT; one patient died at 212 days post-aHSCT from right heart failure. The fourth patient died at day 87 post-aHSCT from sepsis, and the fifth patient developed sinusoidal obstruction syndrome and required repeat liver transplantation but is now on single agent immunosuppression with an mTOR inhibitor. In the three patients who developed tolerance, follow up liver biopsies showed regression of fibrosis and no evidence of rejection. Tolerance induced by aHSCT was associated with a partial deletion of T cell repertoire and replacement with new clones. There was evidence of enhanced peripheral regulation post-aHSCT with short-term (6 months) increases in Tregs and transitional B cells in the peripheral blood. While levels of Tregs returned to baseline in the blood, Tregs persisted in the liver allografts. aHSCT also led to deletion of autoantibodies that are commonly present in patients with PSC.

*Conclusions: These results suggest that aHSCT can induce tolerance in liver transplant recipients although toxicity is a significant problem that needs to be addressed. Tolerance induced by aHSCT likely involves both deletional events and enhanced peripheral regulation.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chruscinski A, Juvet S, Moshkelgosha S, Renner E, Lilly L, Selzner N, Bredeson C, Adeyi O, Fischer S, Demetris A, Zhang J, Epstein M, Clement A, Khalili K, Galvin Z, Humar A, Kim T, Tinckham K, Yi T, Levy G, Atkins H. A Proof-of-Principle Study to Evaluate Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance (ASCOTT) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/a-proof-of-principle-study-to-evaluate-autologous-hematopoietic-stem-cell-transplantation-for-allogeneic-organ-transplant-tolerance-ascott/. Accessed March 8, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.